• Something wrong with this record ?

An Updated Systematic and Comprehensive Review of Cytoreductive Prostatectomy for Metastatic Prostate Cancer

T. Yanagisawa, P. Rajwa, T. Kawada, K. Bekku, E. Laukhtina, MV. Deimling, M. Majdoub, M. Chlosta, PI. Karakiewicz, A. Heidenreich, T. Kimura, SF. Shariat

. 2023 ; 30 (2) : 2194-2216. [pub] 20230210

Language English Country Switzerland

Document type Systematic Review, Journal Article, Review

Persistent link   https://www.medvik.cz/link/bmc23004206

(1) Background: Local therapy is highly promising in a multimodal approach strategy for patients with low-volume metastatic prostate cancer (mPCa). We aimed to systematically assess and summarize the safety, oncologic, and functional outcomes of cytoreductive prostatectomy (cRP) in mPCa. (2) Methods: Three databases were queried in September 2022 for publications that analyzed mPCa patients treated with cytoreductive prostatectomy without restrictions. The outcomes of interest were progression-free survival (PFS), cancer-specific survival (CSS), overall survival (OS), perioperative complication rates, and functional outcomes following cRP. (3) Results: Overall, 26 studies were included in this systematic review. Among eight population-based studies, cRP was associated with a reduced risk of CSS and OS compared with no local therapy (NLT) after adjusting for the effects of possible confounders. Furthermore, one population-based study showed that cRP reduced the risk of CSS even when compared with radiotherapy (RT) of the prostate after adjusting for the effects of possible confounders. In addition, one randomized controlled trial (RCT) demonstrated that local therapy (comprising 85% of cRP) significantly improved the prostate-specific antigen (PSA)-PFS and OS. Overall, cRP had acceptable perioperative complication rates and functional outcomes. (4) Conclusions: Mounting evidence suggests that cRP offers promising oncological and functional outcomes and technical feasibility and that it is associated with limited complications. Well-designed RCTs that limit selection bias in patients treated with cRP are warranted.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004206
003      
CZ-PrNML
005      
20230425141215.0
007      
ta
008      
230418s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/curroncol30020170 $2 doi
035    __
$a (PubMed)36826131
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Yanagisawa, Takafumi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090 Vienna, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo 105-8461, Japan $1 https://orcid.org/0000000274100712
245    13
$a An Updated Systematic and Comprehensive Review of Cytoreductive Prostatectomy for Metastatic Prostate Cancer / $c T. Yanagisawa, P. Rajwa, T. Kawada, K. Bekku, E. Laukhtina, MV. Deimling, M. Majdoub, M. Chlosta, PI. Karakiewicz, A. Heidenreich, T. Kimura, SF. Shariat
520    9_
$a (1) Background: Local therapy is highly promising in a multimodal approach strategy for patients with low-volume metastatic prostate cancer (mPCa). We aimed to systematically assess and summarize the safety, oncologic, and functional outcomes of cytoreductive prostatectomy (cRP) in mPCa. (2) Methods: Three databases were queried in September 2022 for publications that analyzed mPCa patients treated with cytoreductive prostatectomy without restrictions. The outcomes of interest were progression-free survival (PFS), cancer-specific survival (CSS), overall survival (OS), perioperative complication rates, and functional outcomes following cRP. (3) Results: Overall, 26 studies were included in this systematic review. Among eight population-based studies, cRP was associated with a reduced risk of CSS and OS compared with no local therapy (NLT) after adjusting for the effects of possible confounders. Furthermore, one population-based study showed that cRP reduced the risk of CSS even when compared with radiotherapy (RT) of the prostate after adjusting for the effects of possible confounders. In addition, one randomized controlled trial (RCT) demonstrated that local therapy (comprising 85% of cRP) significantly improved the prostate-specific antigen (PSA)-PFS and OS. Overall, cRP had acceptable perioperative complication rates and functional outcomes. (4) Conclusions: Mounting evidence suggests that cRP offers promising oncological and functional outcomes and technical feasibility and that it is associated with limited complications. Well-designed RCTs that limit selection bias in patients treated with cRP are warranted.
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé $7 D006801
650    12
$a cytoredukční chirurgie $7 D065426
650    12
$a nádory prostaty $x terapie $7 D011471
650    _2
$a prostatektomie $7 D011468
650    _2
$a prostatický specifický antigen $7 D017430
655    _2
$a systematický přehled $7 D000078182
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Rajwa, Pawel $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090 Vienna, Austria $u Department of Urology, Medical University of Silesia, 41-800 Zabrze, Poland
700    1_
$a Kawada, Tatsushi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090 Vienna, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8530, Japan
700    1_
$a Bekku, Kensuke $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090 Vienna, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8530, Japan $1 https://orcid.org/0000000300021592
700    1_
$a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090 Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia $1 https://orcid.org/0000000289530272
700    1_
$a Deimling, Markus von $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090 Vienna, Austria $u Department of Urology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany
700    1_
$a Majdoub, Muhammad $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090 Vienna, Austria $u Department of Urology, Hillel Yaffe Medical Center, 169, Hadera 38100, Israel
700    1_
$a Chlosta, Marcin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090 Vienna, Austria $u Clinic of Urology and Urological Oncology, Jagiellonian University, 30-688 Krakow, Poland
700    1_
$a Karakiewicz, Pierre I $u Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC H2X 0A9, Canada
700    1_
$a Heidenreich, Axel $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090 Vienna, Austria $u Department of Urology, Faculty of Medicine and University Hospital of Cologne, 50937 Cologne, Germany
700    1_
$a Kimura, Takahiro $u Department of Urology, The Jikei University School of Medicine, Tokyo 105-8461, Japan $1 https://orcid.org/0000000256731553
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Wahringer Gurtel 18-20, 1090 Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia $u Division of Urology, Department of Special Surgery, The University of Jordan, Amman 19328, Jordan $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA $u Department of Urology, Second Faculty of Medicine, Charles University, 15006 Prague, Czech Republic $u Department of Urology, Weill Cornell Medical College, New York, NY 10021, USA $u Karl Landsteiner Institute of Urology and Andrology, 1090 Vienna, Austria
773    0_
$w MED00165427 $t Current oncology (Toronto, Ont.) $x 1718-7729 $g Roč. 30, č. 2 (2023), s. 2194-2216
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36826131 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425141212 $b ABA008
999    __
$a ok $b bmc $g 1924712 $s 1190415
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 30 $c 2 $d 2194-2216 $e 20230210 $i 1718-7729 $m Current oncology $n Curr. oncol. $x MED00165427
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options